Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Cantargia AB ( (SE:CANTA) ) has provided an update.
Cantargia has published promising preclinical results demonstrating the potential of their CAN10 antibody to inhibit vascular inflammation by targeting IL1RAP. These findings indicate that IL1RAP-targeted therapy could be a novel strategy to mitigate vascular inflammation, with potential implications for treating several inflammatory diseases, including cardiovascular diseases. The study, conducted in collaboration with Örebro University, highlights the antibody’s ability to block inflammatory markers and suggests a translational possibility into human cardiovascular diseases, potentially enhancing Cantargia’s positioning in the biotechnology industry.
More about Cantargia AB
Cantargia AB is a biotechnology company focused on developing antibody-based treatments for life-threatening diseases. The company has established a platform based on the protein IL1RAP, which is involved in various cancer forms and inflammatory diseases. Cantargia’s oncology program includes the antibody nadunolimab (CAN04), primarily studied in combination with chemotherapy for pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer. Their second development program, CAN10, targets serious autoimmune/inflammatory diseases, initially focusing on hidradenitis suppurativa and systemic sclerosis.
YTD Price Performance: -9.82%
Average Trading Volume: 905,081
Current Market Cap: SEK378.9M
For detailed information about CANTA stock, go to TipRanks’ Stock Analysis page.